Klaus OkkenhaugKlaus obtained his B.Sc. in Biochemistry from the University of Victoria, British Columbia, Canada, followed by a Ph.D. in Immunology from the University of Toronto, where he studied CD28 signalling in Rob Rottapel’s lab. In 1999, he moved to London, UK, where he joined Bart Vanhaesebroeck’s group at the Ludwig Institute for Cancer Research as a Postdoctoral Fellow, working on the role of p110δ in immune responses. Klaus joined the Laboratory of Lymphocyte Signalling Lab and Development at the Babraham Institute as a Group Leader in 2003.
The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.
Chellappa S, Kushekhar K, Munthe LA
Journal of immunology (Baltimore, Md. : 1950)
PI3Kδ hyper-activation promotes development of B cells that exacerbate Streptococcus pneumoniae infection in an antibody-independent manner.
Stark AK, Chandra A, Chakraborty K
9 2041-1723:3174 (2018)
Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.
Gyori D, Lim EL, Grant FM
3 2379-3708: (2018)
Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.
Lim EL, Cugliandolo FM, Rosner DR
3 2379-3708: (2018)
Non-Invasive Multiphoton Imaging of Islets Transplanted Into the Pinna of the NOD Mouse Ear Reveals the Immediate Effect of Anti-CD3 Treatment in Autoimmune Diabetes.
Benson RA, Garcon F, Recino A
Frontiers in immunology
9 1664-3224:1006 (2018)
Abdelrasoul H, Werner M, Setz CS
8 2045-2322:1327 (2018)
Kishore M, Cheung KCP, Fu H
47 1097-4180:875-889.e10 (2017)
Stubbs TM, Bonder MJ, Stark AK
18 1474-760X:68 (2017)
Obesity-Induced Metabolic Stress Leads to Biased Effector Memory CD4(+) T Cell Differentiation via PI3K p110δ-Akt-Mediated Signals.
Mauro C, Smith J, Cucchi D
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.
Okkenhaug K, Graupera M, Vanhaesebroeck B
Eil R, Vodnala SK, Clever D
537 1476-4687:539-543 (2016)